Agency Information Collection Activities; Proposed Collection; Comment Request; Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use, 906-908 [E9-213]
Download as PDF
906
Federal Register / Vol. 74, No. 6 / Friday, January 9, 2009 / Notices
trigger approximately 186 efficacy
supplements, each one requiring
approximately 196 hours to revise the
labeling in the application, totaling
36,456 hours. (As stated in the final
rule, in addition to this burden, a
minimal annual reporting burden (fewer
than 7) will continue indefinitely).
Burden Associated with Revised
Labeling for Efficacy Supplements for
Generic Drug Products (§ 201.57) (Table
2)
Based on the projected data estimated
in the final rule, beginning in year 3 and
continuing throughout the 10-year
period analyzed, approximately 42
generic applicants per year must submit
labeling supplements. Approximately
336 already approved generic drug
applications must submit labeling
supplements over the 10-year period
after the effective date of the rule. The
time required to revise and submit this
labeling to FDA is approximately 27
hours per application, totaling 9,072
hours. (As stated in the final rule, in
addition to this burden, a minimal
annual reporting burden associated with
a very small number of generic
applications referencing older drugs
may continue indefinitely).
C. Capital Costs
As discussed in the final rule, a small
number of carton-enclosed products
may require new packaging to
accommodate longer inserts. As many as
5 percent of the existing products
affected by the final rule (i.e., products
with new efficacy supplements,
products approved in the 5 years prior
to the effective date of the rule, and
affected abbreviated new drug
applications) may require equipment
changes at an estimated cost of $200,000
each product.
In the Federal Register of September
29, 2008 (73 FR 56592), FDA published
a 60-day notice requesting public
comment on the information collection
provisions. No comments were received
relating to the paperwork.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN FOR NEW DRUG APPLICATIONS1
Category (21 CFR Section)
No. of Respondents
Annual Burden for Labeling Requirements in §§ 201.56 and 201.57
No. of Responses per
Respondent
85
Total
Responses
1.26
Hours per
Response
107
Total Hours
3,349
Total
358,343
358,343
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL REPORTING BURDENS FOR LABELING REVISIONS TO ALREADY-APPROVED DRUG
PRODUCTS1
Category (21 CFR Section)
No. of Respondents
No. of Responses per
Respondent
Total
Responses
Hours per
Response
Total Hours
Burden associated with revised labeling for applications approved within
5 years prior to June 30, 2006
(§ 201.57)
172
2
344
196
67,424
Burden associated with revised labeling for efficacy supplements submitted on or after June 30, 2006
(§§ 201.56(d) and 201.57)
172
1.08
186
196
36,456
Burden associated with revised labeling for efficacy supplements for generic drug products (§ 201.57)
42
8
336
27
9,072
Total
1There
112,952
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 24, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–175 Filed 1–8–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0657]
mstockstill on PROD1PC66 with NOTICES
BILLING CODE 4160–01–S
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Recommendations
for the Early Food Safety Evaluation of
New Non-Pesticidal Proteins Produced
by New Plant Varieties Intended for
Food Use
AGENCY:
Food and Drug Administration,
HHS.
VerDate Nov<24>2008
16:16 Jan 08, 2009
Jkt 217001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
E:\FR\FM\09JAN1.SGM
09JAN1
907
Federal Register / Vol. 74, No. 6 / Friday, January 9, 2009 / Notices
the information collection provisions of
the guidance document entitled
‘‘Recommendations for the Early Food
Safety Evaluation of New Non-Pesticidal
Proteins Produced by New Plant
Varieties Intended for Food Use.’’
DATES: Submit written or electronic
comments on the collection of
information by March 10, 2009.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Recommendations for the Early Food
Safety Evaluation of New NonPesticidal Proteins Produced by New
Plant Varieties Intended for Food Use
(OMB Control Number 0910–0583—
Extension)
Since May 29, 1992, when FDA
issued a policy statement on foods
derived from new plant varieties, FDA
has encouraged developers of new plant
varieties, including those varieties that
are developed through biotechnology, to
consult with FDA early in the
development process to discuss possible
scientific and regulatory issues that
might arise (57 FR 22984). The guidance
entitled ‘‘Recommendations for the
Early Food Safety Evaluation of New
Non-Pesticidal Proteins Produced by
New Plant Varieties Intended for Food
Use’’ continues to foster early
communication by encouraging
developers to submit to FDA their
evaluation of the food safety of their
new protein. Such communication
helps to ensure that any potential food
safety issues regarding a new protein in
a new plant variety are resolved early in
development, prior to any possible
inadvertent introduction into the food
supply of material from that plant
variety.
FDA believes that any food safety
concern related to such material
entering the food supply would be
limited to the potential that a new
protein in food from the plant variety
could cause an allergic reaction in
susceptible individuals or could be a
toxin. The guidance describes the
procedures for early food safety
evaluation of new proteins in new plant
varieties, including bioengineered food
plants, and the procedures for
communicating with FDA about the
safety evaluation.
The respondents to this collection of
information are developers of new plant
varieties intended for food use.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
First four data components
20
1
20
4
80
Two other data components
20
1
20
16
320
Total
mstockstill on PROD1PC66 with NOTICES
1 There
400
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA estimates the annual total hour
burden for this collection of information
to be 400 hours. This estimate is based
on early food safety evaluations
submitted in the past 3 years. FDA’s
estimate of the time that it would take
a respondent to prepare the data
components of the early food safety
evaluation submission is based on the
agency’s experience with similar
submissions.
Completing an early food safety
evaluation for a new protein from a new
plant variety is a one-time burden (one
VerDate Nov<24>2008
16:16 Jan 08, 2009
Jkt 217001
evaluation per new protein). Based on
its experience over the past 3 years,
FDA estimates that approximately 20
developers will choose to complete an
early food safety evaluation for their
new plant protein. Many developers of
novel plants may choose not to submit
an evaluation because the field testing
of a plant containing a new protein is
conducted in such a way (e.g., on such
a small scale, or in such isolated
conditions, etc.) that cross-pollination
with traditional crops or commingling
of plant material is not likely to be an
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
issue. Also, other developers may have
previously communicated with FDA
about the food safety of a new plant
protein, for example, when the same
protein was expressed in a different
crop.
The early food safety evaluation for
new proteins includes six main data
components. Four of these data
components are easily and quickly
obtainable, having to do with the
identity and source of the protein. FDA
estimates that completing these data
components will take about 4 hours per
E:\FR\FM\09JAN1.SGM
09JAN1
908
Federal Register / Vol. 74, No. 6 / Friday, January 9, 2009 / Notices
evaluation. In table 1 of this document,
row 1 shows that for 20 evaluations, the
total burden for these 4 data
components is 80 hours.
Two data components ask for original
data to be generated. One data
component consists of a bioinformatics
analysis which can be performed using
publicly available databases. The other
data component involves ‘‘wet’’ lab
work to assess the new protein’s
stability and the resistance of the
protein to enzymatic degradation using
appropriate in vitro assays (protein
digestibility study). The paperwork
burden of these two data components
consists of the time it takes the company
to assemble the information on these
two data components to submit to FDA.
We estimate that these two data
components will take 16 hours to
complete (8 hours for each component).
In table 1 of this document, row 2 shows
that for 20 evaluations, the total burden
for these two data components is 320
hours.
Please note that on January 15, 2008,
the FDA Division of Dockets
Management Web site transitioned to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. Electronic
comments or submissions will be
accepted by FDA only through FDMS at
https://www.regulations.gov.
Dated: December 30, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–213 Filed 1–8–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0081] (formerly
Docket No. 2006D–0297)
International Conference on
Harmonisation; Guidance on Q4B
Evaluation and Recommendation of
Pharmacopoeial Texts for Use in the
International Conference on
Harmonisation Regions; Annex on
Test for Extractable Volume of
Parenteral Preparations General
Chapter; Availability
mstockstill on PROD1PC66 with NOTICES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled ‘‘Q4B
Evaluation and Recommendation of
VerDate Nov<24>2008
16:16 Jan 08, 2009
Jkt 217001
Pharmacopoeial Texts for Use in the
ICH Regions; Annex 2: Test for
Extractable Volume of Parenteral
Preparations General Chapter.’’ The
guidance was prepared under the
auspices of the International Conference
on Harmonisation of Technical
Requirements for Registration of
Pharmaceuticals for Human Use (ICH).
The guidance provides the results of the
ICH Q4B evaluation of the Test for
Extractable Volume of Parenteral
Preparations General Chapter
harmonized text from each of the three
pharmacopoeias (United States,
European, and Japanese) represented by
the Pharmacopoeial Discussion Group
(PDG). The guidance conveys
recognition of the three pharmacopoeial
methods by the three ICH regulatory
regions and provides specific
information regarding the recognition.
The guidance is intended to recognize
the interchangeability between the local
regional pharmacopoeias, thus avoiding
redundant testing in favor of a common
testing strategy in each regulatory
region. In the Federal Register of
February 21, 2008 (73 FR 9575), FDA
made available a guidance on the Q4B
process entitled ‘‘Q4B Evaluation and
Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions.’’
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 51, rm. 2201, Silver Spring,
MD 20993–0002; or the Office of
Communication, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
suite 200N, Rockville, MD 20852–1448.
The guidance may also be obtained by
mail by calling CBER at 1–800–835–
4709 or 301–827–1800. Send two selfaddressed adhesive labels to assist the
office in processing your requests.
Submit written comments on the
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H.
King, Sr., Center for Drug
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Evaluation and Research (HFD–
003), Food and Drug
Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 4150,
Silver Spring, MD 20993–0002,
301–796–1242; or
Christopher Joneckis, Center for
Biologics Evaluation and Research
(HFM–1), Food and Drug
Administration, 1401 Rockville
Pike, suite 200N, Rockville, MD
20852–1448, 301–827–0373.
Regarding the ICH: Michelle Limoli,
Office of International Programs
(HFG–1), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–
4480.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry
associations to promote international
harmonization of regulatory
requirements. FDA has participated in
many meetings designed to enhance
harmonization and is committed to
seeking scientifically based harmonized
technical procedures for pharmaceutical
development. One of the goals of
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies.
ICH was organized to provide an
opportunity for tripartite harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
and the United States. The six ICH
sponsors are the European Commission;
the European Federation of
Pharmaceutical Industries Associations;
the Japanese Ministry of Health, Labour,
and Welfare; the Japanese
Pharmaceutical Manufacturers
Association; the Centers for Drug
Evaluation and Research and Biologics
Evaluation and Research, FDA; and the
Pharmaceutical Research and
Manufacturers of America. The ICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation of Pharmaceutical
Manufacturers Associations (IFPMA).
The ICH Steering Committee includes
representatives from each of the ICH
sponsors and the IFPMA, as well as
observers from the World Health
E:\FR\FM\09JAN1.SGM
09JAN1
Agencies
[Federal Register Volume 74, Number 6 (Friday, January 9, 2009)]
[Notices]
[Pages 906-908]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-213]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0657]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Recommendations for the Early Food Safety Evaluation
of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended
for Food Use
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on
[[Page 907]]
the information collection provisions of the guidance document entitled
``Recommendations for the Early Food Safety Evaluation of New Non-
Pesticidal Proteins Produced by New Plant Varieties Intended for Food
Use.''
DATES: Submit written or electronic comments on the collection of
information by March 10, 2009.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-796-3794.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Recommendations for the Early Food Safety Evaluation of New Non-
Pesticidal Proteins Produced by New Plant Varieties Intended for Food
Use (OMB Control Number 0910-0583--Extension)
Since May 29, 1992, when FDA issued a policy statement on foods
derived from new plant varieties, FDA has encouraged developers of new
plant varieties, including those varieties that are developed through
biotechnology, to consult with FDA early in the development process to
discuss possible scientific and regulatory issues that might arise (57
FR 22984). The guidance entitled ``Recommendations for the Early Food
Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant
Varieties Intended for Food Use'' continues to foster early
communication by encouraging developers to submit to FDA their
evaluation of the food safety of their new protein. Such communication
helps to ensure that any potential food safety issues regarding a new
protein in a new plant variety are resolved early in development, prior
to any possible inadvertent introduction into the food supply of
material from that plant variety.
FDA believes that any food safety concern related to such material
entering the food supply would be limited to the potential that a new
protein in food from the plant variety could cause an allergic reaction
in susceptible individuals or could be a toxin. The guidance describes
the procedures for early food safety evaluation of new proteins in new
plant varieties, including bioengineered food plants, and the
procedures for communicating with FDA about the safety evaluation.
The respondents to this collection of information are developers of
new plant varieties intended for food use.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
First four 20 1 20 4 80
data
components
----------------------------------------------------------------------------------------------------------------
Two other data 20 1 20 16 320
components
----------------------------------------------------------------------------------------------------------------
Total 400
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA estimates the annual total hour burden for this collection of
information to be 400 hours. This estimate is based on early food
safety evaluations submitted in the past 3 years. FDA's estimate of the
time that it would take a respondent to prepare the data components of
the early food safety evaluation submission is based on the agency's
experience with similar submissions.
Completing an early food safety evaluation for a new protein from a
new plant variety is a one-time burden (one evaluation per new
protein). Based on its experience over the past 3 years, FDA estimates
that approximately 20 developers will choose to complete an early food
safety evaluation for their new plant protein. Many developers of novel
plants may choose not to submit an evaluation because the field testing
of a plant containing a new protein is conducted in such a way (e.g.,
on such a small scale, or in such isolated conditions, etc.) that
cross-pollination with traditional crops or commingling of plant
material is not likely to be an issue. Also, other developers may have
previously communicated with FDA about the food safety of a new plant
protein, for example, when the same protein was expressed in a
different crop.
The early food safety evaluation for new proteins includes six main
data components. Four of these data components are easily and quickly
obtainable, having to do with the identity and source of the protein.
FDA estimates that completing these data components will take about 4
hours per
[[Page 908]]
evaluation. In table 1 of this document, row 1 shows that for 20
evaluations, the total burden for these 4 data components is 80 hours.
Two data components ask for original data to be generated. One data
component consists of a bioinformatics analysis which can be performed
using publicly available databases. The other data component involves
``wet'' lab work to assess the new protein's stability and the
resistance of the protein to enzymatic degradation using appropriate in
vitro assays (protein digestibility study). The paperwork burden of
these two data components consists of the time it takes the company to
assemble the information on these two data components to submit to FDA.
We estimate that these two data components will take 16 hours to
complete (8 hours for each component). In table 1 of this document, row
2 shows that for 20 evaluations, the total burden for these two data
components is 320 hours.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at https://www.regulations.gov.
Dated: December 30, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-213 Filed 1-8-09; 8:45 am]
BILLING CODE 4160-01-S